What a trial does when someone is harmed

Two reporting systems, and this is the other one

There are two federal reporting systems for harm from a drug, and they are easy to mistake for one.

One runs after a product reaches the market. It collects reports from companies and from the public, it feeds a searchable database, and a companion article on this site covers it in full.

The other runs while a drug is still under investigation. It has different definitions, different clocks and a different destination, and it is the subject here.

The distinction matters more than it sounds. The two systems measure the same word differently, and the difference changes which events get reported at all.

Four definitions that decide everything downstream

The safety reporting section opens with definitions, and they carry more weight than the duties that follow.

An adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

An event is serious if, in the view of either the investigator or the sponsor, it results in one of five outcomes. Death, a life-threatening event, inpatient hospitalization or prolongation of one, persistent or significant incapacity, or a congenital anomaly.

The definition then widens. Important medical events that do not meet those outcomes may still be serious where medical judgment says they may jeopardize the patient and may require intervention to prevent one of them.

Life-threatening means the occurrence places the patient at immediate risk of death. It expressly does not include an event that, had it occurred in a more severe form, might have caused death.

A suspected adverse reaction is any adverse event for which there is a reasonable possibility that the drug caused it. The section defines that phrase too, as evidence to suggest a causal relationship.

The word that is measured against a private document

The fourth definition is the one that separates this system from the marketed one, and almost nobody outside a trial has read it.

An event is unexpected if it is not listed in the investigator brochure, or is not listed at the specificity or severity that has been observed.

Where no brochure is required or available, the comparison shifts to the risk information described in the general investigational plan or elsewhere in the current application.

The marketed system asks a different question. There, an experience is unexpected when it is not listed in the current labeling for the product.

So the same event can be expected in one system and unexpected in the other, because the documents being compared against are different.

The section gives its own examples. Liver necrosis is unexpected by virtue of greater severity where the brochure mentioned only elevated enzymes or hepatitis.

A class effect counts too. An event mentioned as occurring with a class of drugs, but not specifically with the drug under investigation, is unexpected.

What a sponsor has to be reading

Before any report is filed, there is a duty to look, and its scope is unusually broad.

The sponsor must promptly review all information relevant to the safety of the drug obtained or received from foreign or domestic sources.

The section then lists what that includes. Information derived from clinical or epidemiological investigations, animal or laboratory studies, reports in the scientific literature, and unpublished scientific papers.

It also includes reports from foreign regulatory authorities, and reports of foreign commercial marketing experience for drugs not marketed in this country.

Read that list next to a market where much of the available evidence is foreign, preliminary or unpublished. The duty was written to capture exactly that material.

The clocks, and who gets told

The main clock runs fifteen calendar days, and the phrasing is strict. The sponsor must notify as soon as possible, but in no case later than fifteen calendar days after determining that information qualifies.

The notification goes to two places at once. To the agency, and to all participating investigators, meaning every investigator the sponsor is supplying under its applications.

Each report also has to do analytical work. It must identify all previous reports concerning a similar suspected adverse reaction, and analyze the significance of the reaction in light of them.

A faster clock covers the worst outcomes. An unexpected fatal or life-threatening suspected adverse reaction is notified as soon as possible, and in no case later than seven calendar days after initial receipt of the information.

The marketed system has a fifteen-day alert report of its own, and it is not this one. Different trigger, different definition of unexpected, different destination.

The four things that trigger a report

The section names four categories, and only the first is what most people picture.

The first is a suspected adverse reaction that is both serious and unexpected, reportable only where there is evidence suggesting a causal relationship.

The rule then describes what that evidence can look like. A single occurrence of an uncommon event known to be strongly associated with drug exposure.

One or more occurrences of an event not commonly associated with drug exposure but otherwise uncommon in the exposed population.

Or an aggregate analysis showing specific events occurring more frequently in the drug group than in a concurrent or historical control group.

The second category is findings from other studies, whether or not conducted under an application and whether or not conducted by the sponsor, that suggest a significant risk in humans.

The third is findings from animal or laboratory testing that suggest a significant risk in humans, such as reports of mutagenicity, teratogenicity, carcinogenicity, or significant organ toxicity at or near expected human exposure.

The fourth is a clinically important increase in the rate of a serious suspected adverse reaction over the rate listed in the protocol or investigator brochure.

The investigator end of the chain

The duty on the person actually seeing patients is separate, faster and deliberately wider than the sponsor duty.

An investigator must immediately report to the sponsor any serious adverse event, whether or not considered drug related.

That includes events already listed in the protocol or the investigator brochure, so being expected is not a reason to stay silent.

The report must include an assessment of whether there is a reasonable possibility that the drug caused the event.

Study endpoints are handled separately, reported as the protocol describes, unless there is evidence suggesting a causal relationship, in which case the immediate duty returns.

Non-serious events are recorded and reported to the sponsor on the timetable the protocol sets.

A denial written into the rule

One short paragraph anticipates the reason a company might not want to file, and removes it.

A safety report submitted by a sponsor, and any release of it by the agency, does not necessarily reflect a conclusion. Specifically, it does not mean the report constitutes an admission that the drug caused or contributed to an adverse event.

The next sentence goes further. A sponsor need not admit, and may deny, that the submitted information constitutes such an admission.

That paragraph exists because a reporting system only works if reporting is cheap. Making a filing an admission would make silence the rational choice.

It is also a useful reading instruction. A report in either system is a record that something happened, not a finding about why.

The annual report, and the two lists inside it

Once a year, within sixty days of the anniversary of the application taking effect, the sponsor submits a progress report.

It summarises each study, with the number of subjects planned, entered, tabulated by age group, sex and race, completed as planned, and dropped out for any reason.

The summary section then asks for two lists that are hard to write around.

A list of subjects who died during participation in the investigation, with the cause of death for each subject.

And a list of subjects who dropped out during the course of the investigation in association with any adverse experience, whether or not thought to be drug related.

It also carries a narrative or tabular summary of the most frequent and most serious adverse experiences by body system, and a summary of all safety reports submitted during the year.

Where all of it goes, and why you cannot read it

Everything described so far travels to the agency and to the investigators. Very little of it travels anywhere else.

The public disclosure section opens with a sentence worth reading twice. The existence of an investigational new drug application will not be disclosed by the agency unless it has previously been publicly disclosed or acknowledged.

So the agency will not confirm that an application exists. A claim that a compound is under investigation cannot be checked against a public register of applications, because there is no such register.

The data inside an application is handled under the confidentiality provisions written for marketing applications, and under the parallel provisions for biological products.

One door is open, and it is narrow and specific. The agency shall disclose upon request, to an individual to whom an investigational drug has been given, a copy of any safety report relating to the use in that individual.

That is a right belonging to a person who was actually given the drug in a study. It is not a general research tool.

What a reader can take from a system they are outside of

The scope needs restating, because it decides what all of this is worth here. The applicability section opens: "Except as provided in this section, this part applies to all clinical investigations of products". It then names them: those "subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act".

These duties fall on a sponsor and an investigator inside a federal application. A company that has filed nothing carries none of them, and nothing here says otherwise.

What the system does explain is the shape of the evidence a reader can find. Reports flow inward to an agency and to a closed list of investigators, not outward to the public.

It also explains why an absence of published harm reports proves so little. In the investigational system the reports are confidential, and in the marketed system the duties attach to parties this market often does not include.

And it supplies one concrete comparison. A trial measures the word unexpected against a written brochure describing what is already known about the drug.

A page selling a compound rarely has any such document, which means it has nothing to measure a surprise against. That is a difference in kind, not in degree.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.32 — IND safety reporting, including the definitions of adverse event, serious, life-threatening, suspected adverse reaction and unexpected, the duty to review all safety information, the fifteen and seven calendar day clocks, the four reporting triggers, followup, and the disclaimer that a report is not an admission — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 312.64 — Investigator reports, including the duty to immediately report any serious adverse event to the sponsor whether or not considered drug related, the assessment of reasonable possibility, and the handling of study endpoints — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
3. 21 CFR 312.33 — Annual reports, including the sixty-day filing window, the per-study subject tabulations, the summary of adverse experiences by body system, the list of subjects who died with the cause of death for each, and the list of subjects who dropped out in association with an adverse experience — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
4. 21 CFR 312.130 — Availability for public disclosure of data and information in an IND, stating that the existence of an application will not be disclosed unless previously publicly disclosed or acknowledged, and providing that an individual given an investigational drug may obtain a copy of any safety report relating to the use in that individual — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
5. 21 CFR 312.2 — Applicability, whose opening sentence states that except as provided in that section the part applies to all clinical investigations of products subject to the approval provisions of the drug law or the licensing provisions of the public health law — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026